# US 10,369,222 B2 · Compositions and methods of use of phorbol esters for the treatment of stroke > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,369,222 B2 - Document ID: US10369222B2 - Status: Granted - Kind: B2 - Application number: 13/745,742 - Filed: 2013-01-18 - Published: 2014-05-22 - Granted: 2019-08-06 - Earliest claimed: 2012-01-18 - Assignees: Biosuccess Biotech Co. Ltd. - Applicants: Biosuccess Biotech Co. Ltd. - Inventors: Zheng Tao Han; Hung-Fong Chen - Web page: https://patentgrep.com/patent/US10369222B2 ## CPC - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 31/22: of acyclic acids, e.g. pravastatin - A61K 31/23: of acids having a carboxyl group bound to a chain of seven or more carbon atoms - A61K 31/235: having an aromatic ring attached to a carboxyl group - A61K 38/49: Urokinase; Tissue plasminogen activator - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects. ## Claims ### Claim 1 A method for alleviating or treating one or more of the effects of stroke in a mammalian subject comprising administering parenterally to said subject, an effective amount of phorbol ester of Formula II, or a pharmaceutically-acceptable salt, isomer, or enantiomer, thereof wherein the phorbol ester of Formula II is present at an amount from about 10 μg to about 1500 μg, wherein the one or more effects of stroke are paralysis, spatial impairment, impaired judgement, left-sided neglect, memory loss, aphasia, coordination and balance problems, nausea, vomiting, cognitive impairment, perception impairment, orientation impairment, homonymous hemianopsia, impulsivity, or impaired mobility. ### Claim 2 (depends on 1) The method of claim 1, further comprising administering at least one secondary or adjunctive therapeutic agent that is effective in a combinatorial formulation or coordinate treatment regimen with said phorbol ester of Formula II to treat said effects of stroke in said subject. ### Claim 3 (depends on 2) The method of claim 2, wherein the at least one secondary or adjunctive therapeutic agent is administered to said subject in a coordinate administration protocol, simultaneously with, prior to, or after, administration of said phorbol ester to said subject. ### Claim 4 (depends on 2) The method of claim 2, wherein the at least one secondary or adjunctive therapeutic agent is tissue plasminogen activator, an anticoagulant, a statin, fibrate, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitor, beta-blocker, anti-platelet agent, calcium channel blocker, or diuretic. ### Claim 5 (depends on 1) The method of claim 1, further comprising surgical intervention in combination with phorbol ester of Formula II to treat said effects of stroke in said subject. ### Claim 6 (depends on 5) The method of claim 5, wherein the surgical intervention is a carotid endarterectomy, angioplasty, stent placement, craniotomy, insertion of a pacemaker, implantation of a defibrillator, replacement of valves, coronary artery bypass, heart transplantation, endovascular coil emobilization, or patent foramen ovale closure. ### Claim 7 (depends on 1) The method of claim 1, wherein the one or more effects of stroke are paralysis, spatial impairment, impaired judgment, left-sided neglect, memory loss, aphasia, coordination and balance problems, nausea, vomiting, cognitive impairment, perception impairment, orientation impairment, homonymous hemianopsia, or impulsivity. ### Claim 8 A method for reducing symptoms of a stroke comprising administering parenterally, an effective amount of phorbol ester of Formula II, or a pharmaceutically-acceptable salt, isomer, or enantiomer, thereof to a mammalian subject wherein the phorbol ester of Formula II is present at an amount from about 10 μg to about 1500 μg, wherein the one or more symptoms comprise sudden numbness, weakness, sudden confusion, trouble speaking or understanding speech, trouble seeing in one or both eyes, trouble walking, dizziness, loss of balance or coordination, sudden headache, or impaired mobility. ### Claim 9 (depends on 8) The method of claim 8, further comprising administering at least one secondary or adjunctive therapeutic agent that is effective in a combinatorial formulation or coordinate treatment regimen with said phorbol ester of Formula II to treat said effects of stroke in said subject, wherein the secondary or adjunctive therapeutic agent is administered simultaneously with, prior to, or after, administration of said phorbol ester of Formula II. ### Claim 10 (depends on 9) The method of claim 9, wherein the at least one secondary or adjunctive therapeutic agent is an anticoagulant, a statin, fibrate, angiotensin II receptor blockers, anti-platelet agent, angiotensin-converting enzyme inhibitor, beta-blocker, calcium channel blocker, or diuretic.